Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM) announced an underwritten public offering of its common stock, allowing underwriters a 30-day option to purchase an additional 15% of shares. The offering's size and terms are subject to market conditions. Proceeds will be utilized for general corporate purposes, including working capital, research, and marketing. The offering follows a shelf registration statement effective since August 2019. Piper Sandler & Co. and William Blair & Company are the joint book-running managers.

Neuronetics has announced that its NeuroStar Advanced Therapy Outcomes Registry, the largest registry for Major Depressive Disorder (MDD), has enrolled over 10,000 patients across 116 U.S. clinical sites. Results show that 73% of patients experienced significant improvement in depression symptoms, with 52% achieving remission. These findings support the efficacy of NeuroStar’s non-invasive TMS treatment, especially in the context of increasing depression rates. The registry data is paving the way for advancements in treatment protocols for MDD.

Neuronetics, Inc. (NASDAQ: STIM) reported preliminary unaudited revenue results for Q4 and full-year 2020. Q4 revenue is projected between $15.0 and $15.5 million, exceeding guidance of $13.0 to $13.5 million, marking a 21% to 25% increase from Q3 2020. Full-year revenue is expected between $48.7 and $49.2 million, down 22% compared to $62.7 million in 2019 due to COVID-19. The company anticipates revenue recovery in 2021, pending no further COVID-19 disruptions.

MALVERN, Pa., Jan. 07, 2021 - Neuronetics, trading under NASDAQ: STIM, announced its participation in the 23rd Annual ICR Westwicke Conference on January 14, 2021. CEO Keith Sullivan and CFO Steve Furlong will present at 12:15 PM, followed by a panel discussion titled 'Non-Drug Therapeutics: Devices Changing the Treatment Paradigm' at 1:45 PM. The event will feature a live audio webcast accessible on the company's investor relations page, with an archived replay available for 90 days.

Neuronetics focuses on improving patient lives through its NeuroStar® Advanced Therapy System, an FDA-cleared treatment for major depressive disorder.

Neuronetics, Inc. (NASDAQ: STIM) announced an expansion of its sales organization to enhance its commercial capabilities. This initiative includes adding 13 Business Development Managers and 9 NeuroStar Practice Consultants, increasing their respective totals to 22 and 27. The company also supplemented its sales management and clinical training teams. Additionally, on January 4, 2021, it granted 267,358 restricted stock units to 23 new employees under its 2020 Inducement Plan to foster long-term engagement.

Neuronetics, Inc. (NASDAQ: STIM) announced an amendment to its term loan agreement with Solar Capital Partners, enhancing financial flexibility for 2022. The amendment divides a $15 million second tranche loan into three $5 million tranches, contingent on achieving specific revenue targets. Following a $50 million credit facility agreement initiated in March 2020, Neuronetics drew $35 million from the initial tranche and restructured its borrowing options to adapt to challenges posed by COVID-19. This new arrangement is expected to support continued growth and product adoption.

Neuronetics, a medical technology company focused on psychiatric disorders, announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020. CEO Keith Sullivan and CFO Steve Furlong will present, with a pre-recorded webcast available on their investor relations page. Neuronetics markets the NeuroStar® Advanced Therapy System, a non-invasive TMS treatment for major depressive disorder, FDA-cleared for patients not responding to antidepressants. The system is also available in Japan under national health insurance.

Neuronetics announces FDA clearance for TouchStar, a new three-minute intermittent theta burst (iTBS) treatment protocol for Major Depressive Disorder using the NeuroStar® Advanced Therapy System. This innovative protocol, combined with patented Contact Sensing technology, enables clinicians to deliver personalized treatment while ensuring dosage accuracy. TouchStar is set to enhance patient access to effective depression treatments. It adds to the existing NeuroStar treatment options, allowing for significantly shorter sessions. This advancement aims to address rising depression rates and improve patient outcomes.

Neuronetics, Inc. (NASDAQ: STIM) announced its management team will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 12:30 PM ET. A live audio webcast will be accessible on the company's investor relations page, with a replay available for 90 days. Neuronetics focuses on improving quality of life for psychiatric disorder patients through its NeuroStar® Advanced Therapy System, an FDA-cleared, non-invasive treatment for major depressive disorder. The system is also recognized under Japan's national health insurance.